World-renowned Clinical Expert in Urological Oncology Joins Metamark Team

Metamark Appoints Jerome P. Richie as Key Addition to Management Team

(Photo: Business Wire)

CAMBRIDGE, Mass.--()--Metamark, a privately-held company dedicated to providing comprehensive solutions for advanced urological care, announced today that Jerome P. Richie, M.D. will join Metamark’s executive leadership team as Chief Medical Officer, effective July 1, 2015.

“Dr. Richie has an esteemed career in treating urological disorders, and his cutting edge approaches to improving the diagnosis, prognosis and treatment of prostate cancer are world-renowned” said Metamark CEO Shawn Marcell. “We are excited to welcome him to Metamark’s executive leadership team at this important stage of our growth and development.”

Dr. Richie will retire from his current roles, which he has held since 1987, as the Chief (Emeritus) of the Harvard Program in Urology (Longwood Area) at Brigham and Women's Hospital in Boston, as well as the Elliott Carr Cutler Professor of Surgery (Urology) at Harvard Medical School, on June 30. Beginning on July 1, Dr. Richie will head Metamark’s clinical development and medical affairs.

“I am delighted to be joining the Metamark team,” said Dr. Richie. “With the recent launch of ProMark™, Metamark is helping physicians and their patients with prostate cancer to determine the most appropriate treatment options. It is a very exciting time for the company, and I look forward to guiding the clinical development efforts.”

For more information about Metamark, please visit www.metamarkgenetics.com and booth number 2161 at the American Urological Association Annual Meeting, May 15th – May 19th in New Orleans, LA.

Dr. Richie received his M.D. from the University of Texas Medical Branch in Galveston, with residency in General Surgery and Urology at UCLA. In 1977, after 2 years as a Lieutenant Commander in the Navy, he was recruited to Harvard Medical School as an Assistant Professor. During his distinguished career, Dr. Richie has served as Trustee and President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Society of University Urologists and President of the New England Section of the American Urological Association. He is the current President of the Clinical Society of Genito-Urinary Surgeons. He was the long-standing Chairman of the Examination Committee of the Board of Urology, a Governor of the American College of Surgeons, Chairman of the Advisory Council for Urology of the American College of Surgeons and a member of the Urology Residency Review Committee.

He has been awarded the Medal for Outstanding Achievement from the Society of Urologic Oncology, the Distinguished Contribution Award from the American Urological Association, the Russell Scott Award for Continuing Medical Education from the American Foundation of Urology and the Presidential Citation from the American Urological Association. He is the author of more than 400 journal articles and book chapters and three textbooks on the subject of urologic oncology.

About ProMark™

ProMark is designed to improve the accuracy of prognosis for men diagnosed with prostate cancer with biopsy Gleason grades 3+3 or 3+4 for whom standard-of-care medical decision making is currently insufficient. ProMark uses an automated, quantitative multiplex immunofluorescence method to measure the protein levels of 8 biomarkers directly on sections of prostate biopsy tissue. The biomarkers individually and together predict the probability that a cancer has not extended beyond the prostate, or that it has immunological features of aggressive tumors. ProMark test results provide a man’s probability of non-aggressive disease independent from clinico-pathological findings. Results can also be combined with additional clinico-pathologic data to provide even greater confidence to guide appropriate clinical decision-making. A large, blinded, clinical-validation study of ProMark met its primary endpoint, demonstrating that the test can aid in differentiating between aggressive and indolent disease. The research program supporting ProMark has completed four clinical studies, and additional prospective studies are underway. Metamark has offered ProMark testing through the company's CLIA-certified, CAP accredited laboratory in Cambridge, Massachusetts since October 2014. For more information, visit: www.metamarkgenetics.com.

About Metamark

Metamark is a privately held company dedicated to improving cancer care by providing the next generation of diagnostic and prognostic testing. The company is advancing its contribution to oncology through its proprietary genomics and proteomics discovery platforms, a growing clinical research effort, and corporate alliances. Metamark has assembled an integrated portfolio of testing services and products to inform critical decisions at each step of the care pathway in prostate cancer. The company’s interests also include bladder, colon, and breast cancers. For more information, please visit the Metamark website at www.metamarkgenetics.com.

Metamark™ and ProMark™ are trademarks of Metamark.

Contacts

Media:
Feinstein Kean Healthcare
Kelly Schlemm, 617-761-6759
kelly.schlemm@fkhealth.com

Contacts

Media:
Feinstein Kean Healthcare
Kelly Schlemm, 617-761-6759
kelly.schlemm@fkhealth.com